White House Speeds FDA Psychedelic Drug Reviews
April 20, 2026·about 4 hours ago·via Pharmaceutical Commerce

The White House directs the FDA to accelerate reviews for psychedelic treatments targeting mental health issues, aiming to fast-track approvals for therapies like psilocybin and MDMA. This move promises quicker access to innovative options for veterans battling PTSD and everyday Americans crushed by depression - a win for individual liberty over suffocating bureaucracy. Read more about this...